Merck’s Welireg won a label expansion on Thursday in a common form of kidney cancer, weeks ahead of its decision date and without a clear overall survival (OS) benefit.
The drug, belzutifan, will now be available to patients with advanced renal cell carcinoma who’ve already tried a PD-1 or PD-L1 inhibitor and a VEGF-TKI inhibitor. Merck touts Welireg as the first in its class for these advanced patients, who comprise about 15% of new diagnoses, according to the company. The list price is $28,248 for a 30-day supply.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.